The success of implanted devices such as orthopedic implants, cardiovascular prosthesis and neural electrodes is affected by the ability of cells to interact with the exposed device material. Because properties such as surface topology are stable features of the surface, compared to chemical modifications which may be degraded over time, there has been immense interest in directing cell behavior by controlling the topology of materials (Andersson et al.; Chen et al.; Choi et al.; Dalby et al. (2002); Dalby et al. (2005); Diehl et al.; Flemming et al.; Gonsalves et al.; Karuri et al.; Lenhert et al.; Liliensiek et al.; Ma et al.; Re et al.; Teixeira et al. (2003); Teixeira et al. (2006); Yim et al.). Cells have been found to respond differently to smooth surfaces compared to materials with micro or nano-scale roughness in a cell type dependent manner (Yim et al.; Khang et al.; Spatz et al.; Washburn et al.).
Cells adhere to and spread on materials by assembling specialized supramolecular protein complexes called focal adhesions (Bershadsky et al.). Focal adhesion assembly occurs through the ligation of integrin receptors to immobilized ligands such as fibronectin and subsequent clustering of ligated receptors. Variations in nano-scale topography of the substrate can modulate nano-scale integrin ligation and clustering, resulting in changes in adhesion assembly (Spatz et al.; Arnold et al.; Cavalcanti-Adam et al.; Girard et al.). Because focal adhesions are signaling complexes (Bershadsky et al.), such changes in adhesion assembly can alter signaling pathways resulting in the regulation of cell behavior. Indeed, cell behaviors such as motility and adhesion, proliferation and differentiation have been found to be exquisitely sensitive to nano-scale topography of the substrate. A study showed that mesenchymal cells on Si nanowires survived for days, and even differentiated despite being impaled on Si nanowires (Kim et al. 2007a; Pearton et al.).
Stents are often used for palliation of inoperable esophageal, gastric, hepatobiliary, colon, pancreatic and pulmonary cancers. A key challenge in the use of stents is tumor cell in-growth in the stent, which causes re-obstruction (occlusion), requiring early endoscopic removal or even surgery. Untreated, this stent occlusion can lead to difficulty in swallowing (dysphagia), difficulty breathing (dsypnea), intestinal obstruction, jaundice with severe infection and possible death. This introduces severe complications in the management of the cancers, and greatly reduces the quality of the patient's life. One recent approach is to cover the metallic stent with plastic, which attempts to prevent tumor cell adhesion. But this causes undesirable migration of the stent owing to the smooth stent surface. Thus, to improve stent performance, new methods are needed that will minimize tumor cell adhesion, survival and proliferation on the stent.
The subject invention concerns nanorods (also referred to as nanoposts and nanocolumns), compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, a nanorod of the invention is composed of zinc oxide (ZnO). In another embodiment, a nanorod of the invention is composed of titanium dioxide (TiO2), silicon (Si), indium nitride (InN), or gallium nitride (GaN). In a further embodiment, a nanorod of the invention further comprises a coating of SiO2 and/or TiO2. In a specific embodiment, a nanorod of the invention is composed of ZnO coated with SiO2 and/or TiO2. Cell adhesion and survival was reduced on surfaces having a monolayer of upright ZnO nanorods of the present invention. Owing to the uniform distribution of the nanorod monolayer, cells were not able to attach to any flat portion of the substrate. Initial adhesion, lamellipodia formation, dynamic cell spreading and cell survival at 24 hours of three different cell types was greatly reduced on nanorod covered substrates. These results show that upright nanorod type structures can be used for minimizing cell adhesion and survival.
The subject invention also concerns methods for preparing a substrate surface comprising nanorods of the present invention. In one embodiment, a substrate surface is prepared with nanorods composed of ZnO. In another embodiment, a substrate surface is prepared with nanorods composed of TiO2, Si, InN, or GaN. In a further embodiment, a substrate surface is prepared with a nanorod that comprises a coating of SiO2 and/or TiO2. In a specific embodiment, the substrate surface is prepared with a nanorod composed of ZnO coated with SiO2 and/or TiO2. The substrate surface is typically prepared such that the nanorods attached to the surface are generally uniformly spaced apart, densely packed, and/or vertically aligned in a monolayer.
The subject invention also concerns substrates having surfaces with nanorods of the present invention attached thereto. In one embodiment, the substrate is prepared such that the nanorods attached to the surface are generally uniformly spaced apart, densely packed, and/or vertically aligned in a monolayer. In one embodiment, the substrate surface comprises a nanorod composed of ZnO. In another embodiment, the substrate surface comprises a nanorod composed of TiO2, Si, InN, or GaN. In a further embodiment, a substrate surface comprises a nanorod of the invention with a coating of SiO2 and/or TiO2. In a specific embodiment, the substrate surface comprises a nanorod composed of ZnO coated with SiO2 and/or TiO2.
The subject invention also concerns any device, product, apparatus, structure, or material that is capable of or is to be implanted in a living body, such as a human body, wherein the device, product, apparatus, structure, or material is coated on all or a portion of the device, product or apparatus, structure, or material with nanorods of the present invention.
The subject invention also concerns any device, product, apparatus, structure, or material on which cells or an organism might otherwise attach and grow, wherein the device, product, apparatus, structure, or material is coated on all or a portion thereof with nanorods of the present invention to inhibit and/or reduce cellular adhesion, growth, and/or survival to the surface of a substrate of the device, product, apparatus, structure, or material.
The subject invention also concerns methods for delivery of chemicals and drugs into cells. In one embodiment, nanorods of the invention are coated with or attached to a chemical or drug compound and contacted with a cell.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.
The subject invention concerns nanorods, compositions and substrates comprising nanorods, and methods of making and using nanorods and nanorod compositions and substrates. In one embodiment, a nanorod of the invention is composed of zinc oxide (ZnO). In another embodiment, a nanorod of the invention is composed of TiO2, Si, InN, or GaN. In a further embodiment, a nanorod of the invention further comprises SiO2 and/or TiO2. In a specific embodiment, a nanorod of the invention is composed of ZnO coated with SiO2 and/or TiO2. In a more specific embodiment, a nanorod of the invention is composed of ZnO coated with SiO2. Advantageously, nanorods of the invention can be prepared or provided on a substrate or surface at room temperature, thereby allowing for application of nanorods to polymers and other materials that could be destroyed by excessive heat. Nanorods of the invention can be applied to surfaces using industrial dip coating processes and, thus, can be applied to surfaces and materials having complicated geometries.
One aspect of the present invention concerns methods for preventing, inhibiting and/or reducing cellular adhesion, growth, and/or survival to a substrate surface. The present invention can help prevent or control fibrosis around an implanted biomaterial that comprises nanorods of the invention. In one embodiment, a substrate surface is provided with a coating of nanorods of the present invention. In an exemplified embodiment, the nanorods are composed of ZnO. In another embodiment, a nanorod of the invention is composed of TiO2, Si, InN, or GaN. In a further embodiment, a nanorod of the invention further comprises a coating of SiO2 and/or TiO2. In a specific embodiment, the nanorods are composed of ZnO coated with SiO2 and/or TiO2. The nanorods are advantageously provided in densely packed, vertically aligned monolayers. The substrate can be any substrate for which the inhibition or reduction of cellular adhesion, survival, and/or growth is desired. Substrates contemplated within the scope of the invention that can be coated with nanorods of the invention include, but are not limited to, glass, plastics (such as polyethylene and polypropylene), fiberglass, wood, rubber, metals and alloys, ceramics, cloth, polymers, concrete, silicon, and paint. Cells contemplated within the scope of the invention that can be inhibited using nanorods of the invention include, but are not limited to, cells from animals such as mammals (including humans); plants; algae; fungi such as mold; and bacteria. In one embodiment, the cell is a macrophage. In another embodiment, the cell is a fibroblast or an endothelial cell. In a further embodiment, the cell is an osteoclast or osteoblast. In a still further embodiment, the cell is a tumor or cancer cell. The tumor or cancer cell contemplated within the scope of the invention include, but is not limited to, cells from tumors or cancers of the bone, breast, kidney, mouth, larynx, esophagus, stomach, testis, cervix, head, neck, colon, ovary, lung, bladder, skin, liver, muscle, pancreas, prostate, blood cells (including lymphocytes), and brain.
In one embodiment, nanorods of the invention are coated or conjugated with one or more cellular toxins. In a specific embodiment, the cellular toxin is only released from the nanorod in an intracellular environment, e.g., when a cell engulfs or is impaled on a nanorod. Examples of toxins include, but are not limited to, ricin, mitomycin C, cisplatin, botulinum toxin, anthrax toxin, aflatoxin, and the like. In one embodiment, the toxin is attached to a cleavable moiety that can be cleaved by molecules (e.g., by an enzyme) present inside the cell.
In a further embodiment, nanorod surfaces could be designed and engineered or functionalized with a moiety to bind to or to act as an attractant for a target cell, compound, molecule, etc. (e.g., probiotics, beneficial bacteria, drugs, etc.). A specific molecule or surface structure of target bacteria would have strong affinity for the nanorods zones while other bacteria would not. A medical device could be pretreated in specific zones (Pretreated Zones) with probiotics or patient favorable bacteria or with drugs that could be applied and thereby defend against other infections. In another embodiment, a nanorod surface could be designed to enhance surface adhesion of inorganic and organic materials, drugs, drug delivery mechanisms in oral, vascular or similar applications such as by the use of heparin coatings, or coatings that typically elude in a short period of time. In one embodiment, a nanorod of the invention is functionalized with an antibody or an antigen binding fragment thereof, receptor, peptide, nucleic acid, or aptamer that has binding specificity for a target molecule (e.g., an antigen on a target cell or bacterium).
The subject invention also concerns methods for preparing a substrate surface comprising nanorods of the present invention. In one embodiment, a substrate surface is prepared with nanorods composed of ZnO. In another embodiment, a substrate surface is prepared with nanorods composed of TiO2, Si, InN, or GaN. In a further embodiment, a substrate surface is prepared with a nanorod that comprises a coating of SiO2 and/or TiO2. In a specific embodiment, the substrate surface is prepared with a nanorod composed of ZnO coated with SiO2 and/or TiO2. The substrate surface is typically prepared such that the nanorods attached to the surface are generally uniformly spaced apart, densely packed, and/or vertically aligned in a monolayer. However, the height, spacing, and distribution of nanorods on a substrate surface can be modulated as described herein. Nanorods of the invention can be applied to substrate surfaces in zones or regions. These zones or regions are resistant to cellular growth and/or biological contamination. The subject invention also concerns substrates having surfaces with nanorods of the present invention attached thereto. In one embodiment, the substrate is prepared such that the nanorods attached to the surface are generally uniformly spaced apart, densely packed, and/or vertically aligned in a monolayer. In one embodiment, the substrate surface comprises a nanorod composed of ZnO. In another embodiment, the substrate surface comprises a nanorod composed of TiO2, Si, InN, or GaN. In a further embodiment, a substrate surface comprises a nanorod of the invention with a coating of SiO2 and/or TiO2. In a specific embodiment, the substrate surface comprises a nanorod composed of ZnO coated with SiO2 and/or TiO2. Nanorod coatings of the invention typically comprise nanorods that are from about 100 nm to about 5 μm in height, and are from about 5 nm to about 150 nm in diameter. In a specific embodiment, the nanorods are about 500 nm in height and about 50 nm in diameter. In one embodiment, the nanorods can be hexagonal-shaped (viewed in cross-section or needle-shaped. Typically, nanorod coatings of the invention have nanorods spaced apart from between about 5 nm to about 150 nm. In a specific embodiment, the spacing between nanorods is on average about 100 nm. The density of nanorods on the surface of a substrate can be from about 10 rods per square micron to about 1000 or more rods per square micron. In a specific embodiment, the density of nanorods is about 200 to 400 rods per square micron, or about 100 to 200 rods per square micron, or about 110 to about 130 rods per square micron. However, the height, spacing, and distribution of nanorods on a substrate surface can be modulated as described herein. Nanorods of the invention can be applied to substrate surfaces in zones or regions. These zones or regions would be resistant to cellular growth and/or biological contamination.
In a specific embodiment, the substrate contemplated for use in the invention is a substrate for use on an animal body and/or in implantation in an animal body. In one embodiment, the substrate is a biocompatible substrate. In a further embodiment, the substrate is on or part of a material or scaffold for tissue engineering. In another embodiment, the substrate is one that comes into contact with cells or bodily fluids outside of an animal body, for example, in an in vitro application or situation, such as substrates in a heart-lung machine or a kidney dialysis machine. In another embodiment, the substrate is one used for tissue culture wherein inhibition of attachment or adhesion of cells to the substrate is preferred. In a specific embodiment, the substrate is on a tissue culture flask, plate, petri dish, or pipette. In a further embodiment, the substrate is one used on medical products and devices, such as a stent, catheters, bandages, wound dressing and wound treatment materials, stitches, electrical leads, intravascular needles, shunts and drainage tubes, pacemakers, heart valves, aortic prosthesis, ocular implants such as lenses, orthopedic implants such as hip joint or knee implants, implantable drug delivery devices such as insulin or hormone delivery devices, endotracheal tubes, vascular access ports, and the like. Stents contemplated within the scope of the invention include cardiovascular stents and gastrointestinal stents. In a still further embodiment, the substrate is one that is used in food preparation, such as cutting boards and utensils.
The subject invention also concerns any device, product, apparatus, structure, or material that is capable of being or is to be implanted on or in a living body, such as a human body, wherein the device, product, apparatus, structure, or material is coated on all or a portion of the device, product or apparatus, structure, or material with nanorods of the present invention. Examples include medical devices such as bandages, wound dressing and wound treatment materials, catheters, pacemakers, stents, heart valves, aortic prosthesis, ocular implants such as lenses, orthopedic implants such as hip joint or knee implants, implantable drug delivery devices such as insulin or hormone delivery devices, and the like. In one embodiment, the coatings of nanorods of the invention on devices and products can prevent or inhibit cell adhesion and survival, inhibit or prevent fibrotic encapsulation, inhibit or prevent the growth of bacteria, and inhibit or prevent the growth of biofilms. In a specific embodiment, a stent is coated with a nanorod composed of ZnO, optionally coated with SiO2 and/or TiO2. Stents contemplated within the scope of the invention include, but are not limited to, those for palliation of tumors and cancers in a patient, and those for cardiovascular and gastrointestinal use. Nanorod coated stents of the invention can prevent or reduce platelet adhesion and/or prevent or minimize fibrotic encapsulation by modulating adhesion of macrophages. In another specific embodiment, a bandage or wound dressing material is coated with a nanorod composed of ZnO, optionally coated with SiO2 and/or TiO2.
The subject invention also concerns any device, product, apparatus, structure, or material on which cells or an organism might otherwise attach and grow, wherein the device, product, apparatus, structure, or material is coated on all or a portion thereof with nanorods of the present invention to inhibit and/or reduce cellular adhesion, growth, and/or survival to the surface of a substrate of the device, product, apparatus, structure, or material. For example, in one embodiment, nanorods of the present invention are provided on the walls, floors, or lining of a fresh-water or marine aquarium. In another embodiment, the hull of a watercraft or boat vessel is provided with a coating of nanorods of the invention. In still another embodiment, a dock piling or pier, and/or the hardware associated therewith, is provided with a coating of nanorods of the invention. In another embodiment, a surface that is exposed to damp or wet conditions that favor the growth of organisms (e.g., mold, mildew, and/or fungus), such as a shower, tub, toilet, urinal, or sink is provided with a surface coating of nanorods of the invention. In one embodiment, grout or caulk is coated with the nanorods. In another embodiment, filter elements, such as for a gas (e.g., air) or liquid (e.g., water) filter, are coated with nanorods of the invention. In a specific embodiment, the coating of nanorods is provided on the filter element of a mask such as worn in a hospital or surgical environment. In another embodiment, the substrates of a medical device, or parts or portions thereof, that come into contact within cells or bodily fluids of a subject or patient is provided with a surface coating of nanorods of the invention. Examples of medical devices contemplated include heart-lung machines and kidney dialysis machines.
The subject invention also concerns methods for delivery of chemicals and drugs into cells. In one embodiment, nanorods of the invention are coated with or attached to a chemical or drug compound and contacted with a cell. The nanorods are engulfed by the cells and the chemical or drug is thereby delivered into the cell. In one embodiment, the drug or chemical can be attached or coated to the nanorod via a linker molecule that can be cleaved (e.g., by enzymes present in a cell) once the nanorod is inside the cell, thereby releasing the drug or chemical from the nanorod. In one embodiment, the drug is a synthetic compound such as a pharmaceutical. In another embodiment, the drug or chemical is biologically-derived such as a protein, peptide, or nucleic acid such as DNA or RNA. Thus, one aspect of the subject invention concerns methods for transforming cells with a nucleic acid, comprising contacting the cells with a nanorod(s) of the invention coated with the nucleic acid to be used to transform the cell, wherein the nucleic acid is released from the nanorod once inside the cell.
The subject invention also concerns methods for synthesizing a nanorod of the present invention on the surface of a substrate. In one embodiment, a solution of zinc acetate is mixed with a base solution (such as NaOH) for several hours with heating. In one embodiment, the solutions are mixed for 1 to 3 hours at between 50° C. to 70° C. Zinc oxide nanoparticles that form are then coated onto a substrate, followed by heating the coated substrate. In one embodiment, the ZnO particles are spin coated onto the substrate. The heating can be from 100° C. to 200° C. The coated substrate is then contacted with an aqueous nutrient solution that comprises about 20 mm zinc nitrate hexahydrate (Zn(NO3)2.6H2O) and about 20 mm hexamethylenetriamine (C6H12N4) (Kang et al., 2007). The growth of nanorods can be arrested by removing the substrate from the nutrient solution, rinsing (e.g., with water), and drying. Optionally, the nanorods can be coated with SiO2 or TiO2. In one embodiment, SiO2 is deposited on the nanorods using a plasma enhanced chemical vapor deposition system using N2O and SiH4 as precursors. Patterns of nanorods of the invention can be produced on a substrate surface using conventional photoresist (PR) lithography.
Nanorods of the invention can be used on substrates to limit biological contamination of products commonly used in non-sterile environments:
a. Resist the growth of bacteria or other contaminants in triage situations.
b. Permit the application and extended use of medical devices in non-sterile environments such as bandages, stitches, catheters, etc.
c. Reduce the frequency of changing or redressing wounds or replacing a medical device. For example, replacing the electrical leads coming out from a patient's body and connecting to an external power supply for a Ventricular Assist Device.
Nanorods of the invention can be designed with conductive or semi-conductive properties. The nanorods can be grown on silicon or other substrates or on top of a circuit pathway. Application of voltage and current to the circuit pathways can energize the nanorods and surrounding surfaces. When alternating or direct current is applied to the circuit, the nanorod surface can exhibit the following:
The subject invention also concerns smart medical devices utilizing surfaces or zones composed of nanorod electrodes or functionalized nanorod surfaces that can be used to detect environmental conditions, the level of cellular activity, or other events occurring at specific locations on the surface of the device. Information would be passed back to the device or user for interventions such as: change out the device; administer a drug; alert user about possible contamination; or take a predetermined action.
Nanorods of the invention can also be used in military applications. In one embodiment, nanorods of the invention are used to inhibit the adhesion and growth of biological agents and biologically active materials. Nanorods can also be used with other chemical warfare agents to provide a protective effect.
The synthesis of nanorods composed of TiO2, Si, InN, and GaN has been described in Cai et al. (2007), Jia et al. (2007), Joo et al. (2005), Kryliouk et al. (2007), Kuo et al. (2005), Liliental-Weber et al. (2007), Patzig et al. (2008), Tanemura et al. (2006), and Yan et al. (2008).
As shown herein, the adhesion and viability of fibroblasts, umbilical vein endothelial cells, and capillary endothelial cells are greatly altered on ZnO nanorods of the invention. Cells adhered less and spread less on ZnO nanorods than on the corresponding ZnO flat substrate. Scanning electron microscopy indicated that cells were not able to assemble lamellipodia on nanorods. Time-lapse phase contrast imaging showed that cells initially adherent to nanorods are unable to spread. This suggests that the lack of initial spreading on ZnO nanorods may cause cell death.
The results herein indicate a lack of focal adhesion assembly in cells cultured on ZnO nanorods of the invention. In one embodiment, the spacing between the ZnO nanorods of the invention is approximately 100 nm. Recent work by Arnold et al. showed that focal adhesion assembly requires that the spacing between ligated integrins be less than 70 nm (Arnold et al.). Thus, it is possible that integrin clustering does not occur effectively in cells on ZnO nanorods and therefore prevents focal adhesion assembly. Cells on nanorods of the invention also have no visible lamellipodia. As initial adhesion is required to polymerize actin filaments (Lauffenburger et al.), the lack of lamellipodia is probably due to an inability of cells to establish strong initial adhesion to the substrate, thereby altering the dynamics of cell spreading. The observations described herein of altered cell spreading dynamics are consistent with observations by Cavalcanti-Adam et al. who observed similar behavior on RGD (Arginine-Glycine-Aspartic acid) nanopatterned substrates (Cavalcanti-Adam et al.). Results herein can therefore be explained by a mechanism in which abnormal assembly of focal adhesions due to an inability to cluster integrins contributes to decreased cell spreading on nanorods. Because a lack of cell spreading can cause cell death in each of the cell types studied here (Chen et al.; Re et al.), decreased spreading is associated with decrease in cell survival on nanorods of the invention.
It is interesting to contrast the results herein with the work of Kim et al. (2007a). Kim et al. found that nanowires are engulfed by cells, but do not induce apoptosis. Because the nanowires were sparse in the Kim et al. study (20-30 nanowires exposed to each cell), it is likely that cells attach to the flat portions of the substrate and therefore survived. In the experiments of the present invention, each cell was exposed to 60,000 to 150,000 nanorods. Thus, it is possible that a large number of nanorods were engulfed by cells. If this is the case, then toxicity due to nanorod engulfment may cause cell death. Phagocytosed ZnO nanoparticles have been reported to be cytotoxic in vascular endothelial cells (Gojova et al.). The work by Kim et al. showed that DNA immobilized on Si nanowires could be delivered into cells (Al-Hilli et al.). Thus, the efficiency of ZnO nanorods in preventing cell survival can be further enhanced by chemically conjugating toxins to the surface, and delivering these into the cell through penetration and subsequent cleavage.
The nanorod aspect ratio probably plays an important role in the observed response. For example, Curtis and coworkers do not report a large decrease in cell survival, although they also observed decreased cell spreading on nanoposts (Al-Hilli et al.). The diameter in these studies was 100 nm and the height was 160 nm. Curtis et al. report that nanocolumns are not engulfed by cells. As the aspect ratio of nanorods of the invention is more similar to Kim and co-workers (Kim et al., 2007a) where the nanowires were engulfed by cells, this could be another reason for the decreased cell survival in experiments described herein. Additionally, the observations herein of reduced cell adhesion and survival on nanorods are consistent with at least one recent study which employed an aspect ratio similar to the one used in this paper (Choi et al.).
Controlling cell behavior with biomaterials is necessary for the success of tissue engineering scaffolds, biomedical implants and implanted drug delivery devices. Collectively, the results herein indicate that ZnO nanorods of the invention can be used as an adhesion-resistant biomaterial capable of inducing death in anchorage-dependent cells.
Densely packed upright SiO2 nanorods were created by coating hydrothermally grown ZnO nanorods with a thin layer of SiO2 using the plasma enhanced chemical vapor deposition (PECVD) technique. It was found that cell numbers were greatly reduced by nearly two orders of magnitude for fibroblasts and an order of magnitude for HUVECs on SiO2 coated nanorods. Those cells that were adherent were unable to survive on the nanorods. When cultured on a patterned surface where flat circular areas were surrounded by dense nanorods, cells spent the majority of time confined on the flat areas. This indicates that patterning nanorods is a novel approach to pattern cell adhesion.
Fabrication of ZnO nanorods. ZnO nanorods were made by a solution-based hydrothermal growth method (Greene et al.; Kang et al.; Pacholski et al.). First, ZnO nanoparticles were prepared by mixing 10 mM zinc acetate dehydrate (Sigma Aldrich, St. Louis, Mo.) with 30 mM of NaOH (Sigma Aldrich, St. Louis, Mo.) at 58° C. for 2 hours. Next, ZnO nanoparticles were spin-coated onto the substrate several times and then post-baked on a hot plate at 150° C. for better adhesion. The substrate with these ‘seeds’ was then suspended upside down in a Pyrex glass dish filled with an aqueous nutrient solution. The growth rate was approximately 1 μm per hour with 100 ml aqueous solution. To arrest the nanorod growth, the substrates were removed from solution, rinsed with de-ionized water and dried in air at room temperature.
Preparation of substrates for cell culture. For control substrate, we used 22 mm square glass cover slips (Corning, Inc., Lowell, Mass.) and ZnO flat substrates (Cermet, Inc., Atlanta, Ga.). Before use, each substrate was sterilized with UV for 5 minutes and cleaned in 70% ethanol and de-ionized water. After drying substrates in air at room temperature, they were treated with 5 μg/ml human fibronectin (FN) (BD biosciences, Bedford, Mass.). After overnight incubation with FN at 4° C., the substrates were washed twice with PBS. Cells of the same concentration and volume (i.e., same number) were then seeded on each substrate.
Cell culture and adhesion. Cells of three different types were seeded on FN-coated substrates. NIH 3T3 fibroblasts were cultured in DMEM (Mediatech, Inc., Herndon, Va.) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, Utah). Human umbilical cord vein endothelial cells (HUVECs) were cultured with EBM-2 Basal Medium and EGM-2 SingleQuot Kit (Lonza, Walkersville, Md.). Bovine capillary endothelial cells (BCEs) were pre-cultured with low-glucose DMEM supplemented with 10% fetal calf serum (FCS) (Hyclone, Logan, Utah).
Immunostaining. After 24 hours of cell seeding, non-adherent cells were removed with two gentle washes with PBS. The samples were fixed with 4% paraformaldehyde for 20 min and washed several times with PBS. Fixed cells were immuno-stained for vinculin and stained for actin using our previously reported methods (Lele et al.; Parker et al.). Briefly, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and treated with mouse monoclonal anti-vinculin antibody (Sigma Aldrich, St. Louis, Mo.), followed by goat anti-mouse secondary antibody conjugated with Alexa Fluor 488 (Invitrogen, Eugene, Oreg.). Actin was stained with phalloidin conjugated with Alexa Fluor 594 (Invitrogen, Eugene, Oreg.). Cells were then imaged on a Nikon TE 2000 epifluorescence microscope using FITC and Texas Red filters. All images were collected using the NISElements program (Nikon).
Cell viability assay. The live/dead viability/cytotoxicity kit for mammalian cells (Invitrogen, Eugene, Oreg.) was used for quantifying adherent cell viability on each substrate. Cells were incubated at 30-45 minutes with calcein AM (2 μM for fibroblast, 5 μM for endothelial cells) and ethidium homodimer-1 (EthD-1) (4 μM for fibroblast, 1.5 μM for endothelial cells) (Michikawa et al.). Next, epifluorescence images of five random fields were collected on a Nikon TE 2000 inverted microscope using a 10× lens. The average number of cells adherent on each substrate, the number of adherent live cells (stained green with calcein AM) and adherent dead cells (stained red with EthD-1) were quantified from these images using the NIS-Elements program (Nikon). The experimental data was pooled and used for statistical comparisons using the Student's T-test.
Scanning electron microscopy (SEM). Cells were prepared for SEM by fixation with 2% glutaraldehyde buffered in PBS and post-fixed in 1% osmium tetroxide. Samples were next dehydrated in graded ethanol concentrations. Critical point drying (CPD) was performed on a Bal-Tec 030 instrument (ICBR Electron Microscopy Core Lab, University of Florida) followed by ebeam metal deposition (Ti/Au, 10/50 Å). SEM was performed on a Hitachi S-4000 FESEM (ICBR Electron Microscopy Core Lab, University of Florida). Images of samples were taken at 1.8-8.0 k× magnifications.
Time lapse imaging. Cells which had been pre-cultured as mentioned above were trypsinized and resuspended in bicarbonate-free optically clear medium containing Hank's balanced salts (Sigma Aldrich, St. Louis, Mo.), L-glutamine (2.0 mM), HEPES (20.0 mM), MEM essential and non-essential amino acids (Sigma Aldrich, St. Louis, Mo.), and 10% FCS (Lele et al.). Cells were passed onto FN-coated glass or ZnO nanorods, and phase contrast imaging performed overnight for 10 hours on the Nikon TE 2000 microscope. Images were collected every 1 minute, using a 20× objective.
All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
Following are examples that illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
Shown in
Because there was a focus on the effect of topology on cells, it was important to choose an appropriate control for statistically comparing effects of nanorods on cells. As the material itself can have effects on protein adsorption and cell adhesion, a topologically smooth substrate made of ZnO—a thin film commercially available from Cermet Inc.—was chosen. AFM images of this substrate are shown in
The influence of ZnO nanorods of the present invention on cell spreading was also investigated. Cells in vitro spread by assembling focal adhesions and stress fibers.
The results of Kim et al. (2007a) suggest that mesenchymal stem cells can survive on silicon nanowires for several days. Cells in Kim et al. (2007a) were only exposed to 20-30 nanowires per cell. To investigate if a confluent monolayer of ZnO nanorods of the present invention supports cell survival, the total cell number, and fraction of live and dead cells in an adherent population at 24 hours of culture was quantified. The total number of adherent cells and of adherent live cells at the end of 24 hours was greatly decreased on nanorods of the present invention compared to flat substrates (
A recent study showed that cells on needle-like nanostructures only assemble filopodia (Choi et al.). To investigate this possibility for ZnO nanorods, SEM studies on NIH 3T3 fibroblasts cultured on ZnO nanorods of the present invention were performed (
The results of Kim and co-workers showed that Si nanowires with diameter similar to our nanorods are engulfed by cells (Kim et al., 2007a). This raises the possibility that cells may spread initially on the nanorods but undergo apoptosis due to engulfment of nanorods at longer times. To clarify this, time-lapse imaging was performed for studying dynamic cell spreading on nanorods (
Fabrication of ZnO nanorods. ZnO nanorods were made by a solution-based hydrothermal growth method (Lee et al., 2008). First, ZnO nanoparticles were prepared by mixing 10 mM zinc acetate dehydrate (Sigma Aldrich, St. Louis, Mo.) with 30 mM of NaOH (Sigma Aldrich, St. Louis, Mo.) at 58° C. for 2 h. Next, ZnO nanoparticles were spin-coated onto the substrate several times and then post-baked on a hot plate at 150° C. to promote adhesion. Seeded substrates were then suspended upside down in a Pyrex glass dish filled with an aqueous nutrient solution. The growth rate was approximately 1 μm/h with 100 ml aqueous solution containing 20 mM zinc nitrate hexahydrate and 20 mM hexamethylenetriamine (Sigma Aldrich, St. Louis, Mo.). To arrest the nanorod growth, the substrates were removed from solution, rinsed with de-ionized water and dried in air at room temperature. Zinc oxide was deposited for relatively “flat” control samples of sputtered ZnO using a Kurt Lesker CMS-18 Multi Target Sputter Deposition system.
Macrophage generation. Bone marrow-derived macrophages were generated from 7-10 week-old C57BL6/J mice using a 10 day culture protocol. Animals were handled in accordance with protocol approved by the University of Florida. Briefly, mice were euthanized by CO2 asphyxiation followed by cervical dislocation and tibias and femurs were harvested for isolating marrow cells. The marrow cells were obtained by flushing the shaft of the bones with a 25 gauge needle using RPMI (Hyclone Laboratories Inc, Logan, Utah) medium containing 1% FBS (Hyclone Laboratories Inc, Logan, Utah) and 1% PSN (Hyclone Laboratories Inc, Logan, Utah). The red blood cells (RBCs) were removed by lysing with ACK lysis buffer (Lonza, Walkersville, Md.) followed by plating on tissue culture flasks for 2 days in order to remove adherent cells. After 48 hours (day 2), the floating cells were transferred to low attachment plates and cultured with 1 ng/ml IL-3 for expansion of the macrophage precursor cells. The cells were cultured in macrophage culture media consisting of Dulbecco's Modified Eagle's Medium (DMEM)/F12(1:1) (Cellgro, Herndon, Va.) medium containing 1% PSN, 1% L-glutamine (Lonza, Walkersville, Md.), 1% Non essential amino acids (NEAA) (Lonza, Walkersville, Md.), 1% Sodium pyruvate (Lonza, Walkersville, Md.), 10% Fetal Bovine Serum (FBS) and 10% L-929 cell conditioned media. (LCCM). To produce LCCM, L-929 cells were grown to a confluent monolayer in 150 cm2 tissue culture flasks. 50 ml media was added to each flask for 7 days after which all the media in the flask was replaced with fresh media for 7 additional days. The media collected at day 7 and 14 was pooled, sterile filtered and stored at −20° C. The LCCM serves as a source of Macrophage Colony Stimulating Factor (MCSF) which pushes the differentiation of marrow cells towards the macrophage phenotype. Half of the media in the wells was exchanged on day 4 with fresh macrophage culture media. At day 6, cells from low attachment plates were transferred to tissue culture 6 well plates to allow macrophage adhesion and maturation. At day 8 all the media in the wells was replaced with fresh media and at day 10 of culture the cells are ready for experiment. The purity of the macrophage culture was verified by staining for CD11b and F4/80 murine macrophage markers and analyzed using flow cytometry.
Preparation of substrates for macrophage culture. The ZnO nanorods were grown on 22 mm square glass coverslips. 22 mm square glass coverslips (Fisherbrand, Fisher scientific) were used as reference substrates and sputtered ZnO “flat” substrate served as a control for surface topography. Prior to cell seeding the ZnO substrates-nanorod and sputtered, were sterilized by alcohol wash for 15 min followed by UV treatment for 15 min. The glass coverslips were O2 plasma etched followed by alcohol wash and UV treatment.
Macrophage culture on ZnO substrates. In order to study adhesion of macrophages on nanorods over several hours, macrophages were cultured overnight on ZnO nanorods. Phase contrast imaging was performed overnight for 10 h on the Nikon TE 2000 microscope. Images were collected every 1 min, using a 40× objective.
Adhesion and viability studies were performed using macrophages pre-loaded with calcein (Keselowsky et al., 2003). Briefly, macrophages were loaded 1 μg/ml calcein-AM (AnaSpec Inc, San Jose, Calif.) in 2 mM dextrose solution by incubating it at 37° C. for 20 min, pelleted and resuspended in macrophage culture media. Macrophages in this cell suspension were counted by hemocytometer and 500,000 cells were seeded onto substrates for 16 hours. The number of cells adherent on the surfaces was quantified at 3 and 16 hours post seeding. At the time of quantification, 7-AAD (Beckman Coulter, Fullerton, Calif.) was added to the wells as per manufacturer's instruction. Adherent cells that retained calcein and did not stain with 7-AAD were counted as live while 7-AAD positive cells were counted as dead. Three images were taken per sample for quantifying the total adherent, live and dead cells. Data was averaged from 6-8 replicates obtained from 3 separate runs.
In order to test the non-contact based cytotoxicity of ZnO substrates, an equal number of macrophages in 6 well plates were exposed to the three surfaces inverted on Viton O-rings (
In vivo response to ZnO nanorod coating. As a pilot study of the foreign body response mounted by the body against ZnO nanorod coated biomaterials, polyethylene terephthalate (PET) discs coated with ZnO nanorods were implanted subcutaneously on the mouse's back on the dorsal side of the thorax. Uncoated PET discs served as a control. Due to the toxic effect of ZnO NR on macrophages observed during the in vitro studies we conducted a pilot run with 2 NR coated discs implanted in a mouse. Xx mice served as controls.
2 discs (7 mm diameter, 0.5 mm thick) were cut from PET sheets and ZnO nanorods were grown on its surface as described in section 2.1. Prior to implantation, the nanorod coated and uncoated discs were sterilized by dipping in 70% ethanol. 2 discs were implanted subcutaneously on the mouse's back in accordance with protocol approved by the University of Florida IACUC committee. The wounds were closed with wound clips which were removed at day 7 after implantation. PET discs were explanted at 14 days, formalin-fixed and paraffin-embedded. Histological sections (5 μm thick) were stained with hemotoxylin and eosin stain for nuclei (dark blue) and collagen (pink) and examined by phase-contrast microscopy.
Statistical Analysis. Statistical analyses were performed using general linear nested model ANOVA, linear regression analysis using Systat (Version 12, Systat Software, Inc., San Jose, Calif.). Pair-wise comparisons were made using Tukey's Honestly-Significant-Difference Test with p-values of less than or equal to 0.05 considered to be significant.
In order to generate a large number of highly purified macrophages, we used a modified 10 day culture protocol (Cunnick et al., 2006; Stanley, 1997) for generating macrophages from bone marrow precursor cells. In order to confirm macrophage culture purity, we determined the percentage of cells that matured to macrophages by staining with CD11b and F4/80, murine macrophages markers and analyzed using flow cytometry. The percentage of cells co-expressing CD11b and F4/80 was ˜90% (
In order to investigate effect of surface topology on macrophage spreading and adhesion we studied macrophage spreading on ZnO nanorods over several hours post seedin. The ZnO nanorod surface was coated with fibronectin by overnight incubation followed by PBS wash. Macrophages were seeded on the nanorod substrate and allowed to adhere for 1 hour after which a time lapse video of a single cell was taken in order to study the change in spread area of the cell over time. Initially the cell was well spread for the first 2 hours however over the next couple of hours its area of cell spreading was decreased significantly. Due to the unfavorable surface topology of the nanorods, macrophages may fail to assemble focal complexes required for cell adhesion and spreading.
Several reports have suggested that nanotopography controls cell adhesion and viability for example Lee et al have reported decreased adhesion and viability of endothelial cells on ZnO nanorods as compared to ZnO flat substrate (Lee et al., 2008). In order to determine whether the nanotopography of ZnO nanorods was able to modulate macrophage adhesion, we first investigated contact-dependent response of macrophages to ZnO nanorod surface as compared to sputtered ZnO substrate (as a relatively “flat” ZnO surface) and O2-plasma etched cleaned glass coverslips as a reference. To determine the viability of macrophages in contact with substrates, equal numbers of calcein-loaded macrophages were plated on the 3 substrates for 16 hours. Cells maintaining calcein loading and 7-AAD exclusion were counted as live while the ones that either retained or released calcein but stained for 7-AAD were counted as dead. The sum of the live and dead cells was computed for total adherent cell number.
At both 3 and 16 hours, the total number of live cells adherent on the ZnO flat substrate and ZnO nanorods was greatly reduced as compared to the reference glass surface (
At 3 hours the total number of cells adherent on glass and ZnO flat substrate was not significantly different, however the number of dead cells was significantly higher (3× compared to glass) on ZnO substrate (
As indicated by our results of contact based toxicity of ZnO, both sputtered ZnO and nanorods have a cytotoxic effect on the macrophages. One of the possible mechanisms by which ZnO can induce cytotoxicity is by dissolving into the cell media and being internalization by macrophages. In order to test this hypothesis of ZnO dissolution in cell media, we incubated the macrophages in media with the substrates inverted at media level as shown in
Although our in vitro data provides a valuable insight into the cytotoxic effect of ZnO surfaces and particularly nanorods on macrophages, it cannot completely represent the response of the body to a material implanted in vivo. In order to study tissue responses to ZnO coated biomaterials which are more clinically relevant; we performed a pilot study of subcutaneous implantation of ZnO nanorod coated PET discs. One of the standard methods to evaluate chronic inflammation to synthetic materials is measurement of fibrous capsule thickness following subcutaneous implantation (Anderson, 2001). PET discs coated with ZnO nanorods were implanted subcutaneously for 14 days to assess the effect of the ZnO nanorod coating on the foreign body reaction and fibrous encapsulation of implanted materials. PET discs without any coating were implanted as controls. After 2 weeks of implantation, the uncoated PET discs implanted subcutaneously on the mice's back had a smooth acellular fibrous capsule (
Fabrication of nanorods. ZnO nanorods were made by a solution-based hydrothermal growth method (Kang et al., 2007). First, ZnO nanocrystal seed solutions were prepared by mixing 15 mM zinc acetate dihydrate (Sigma Aldrich, St. Louis, Mo.) with 30 mM of NaOH (Sigma Aldrich, St. Louis, Mo.) at 60° C. for 2 h. Next, ZnO nanocrystals were spin-coated onto the substrate and then post-baked on a hot plate at 200° C. for better adhesion. The substrate with these seeds was then suspended upside down in a Pyrex glass dish filled with an aqueous nutrient solution. The growth rate was approximately 1 μm per hour with 100 ml aqueous solution containing 20 mM zinc nitrate hexahydrate and 20 mM hexamethylenetriamine (Sigma Aldrich, St. Louis, Mo.). To arrest the nanorod growth, the substrates were removed from solution, rinsed with de-ionized water and dried in air at room temperature. SiO2 was deposited with a Unaxis 790 plasma enhanced chemical vapor deposition (PECVD) system at 50° C. using N2O and 2% SiH4 balanced by nitrogen as the precursors as reported before (Chu et al., 2008). Patterned nanorods were fabricated by conventional photoresist (PR) lithography (Kang et al., 2007). A glass coverslide was processed with negative PR (SU-8 2007, Microchem) so that a pattern with 50 micron circles was formed on the surface. The substrate was then post-baked at 110 C.° for 30 min. The processed substrate was spin-coated with ZnO nanocrystals as seed materials and nanorods were grown on the substrate with an aqueous nutrient solution. The negative PR was removed by PG remover in a warm bath at 60 C.° for 30 min.
Cell culture. For control substrate, we used 22 mm square glass cover slips (Corning, Inc., Lowell, Mass.). Before use, each substrate was sterilized with UV for 5 min and cleaned in 70% ethanol and de-ionized water. After drying substrates in air at room temperature, they were treated with 5 μg/ml human fibronectin (FN) (BD biosciences, Bedford, Mass.). After overnight incubation with FN at 4° C., the substrates were washed twice with PBS. NIH 3T3 fibroblasts were cultured in DMEM (Mediatech, Inc., Herndon, Va.) supplemented with 10% donor bovine serum (DBS) (Hyclone, Logan, Utah). Human umbilical cord vein endothelial cells (HUVECs) were cultured in EBM-2 Basal Medium and EGM-2 Single Quot Kit (Lonza, Walkersville, Md.). Cell suspensions of the same concentration and volume (i.e. same number of cells) were then seeded on each substrate.
Immunostaining and cell viability assay. After 24 hours of cell seeding, non-adherent cells were removed with two gentle washes with PBS. The samples were fixed with 4% paraformaldehyde for 20 min and washed several times with PBS. Fixed cells were immuno-stained for vinculin and stained for actin and nucleus using our previously reported methods (Lee et al., 2008). Briefly, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and treated with mouse monoclonal anti-vinculin antibody (Sigma Aldrich, St. Louis, Mo.), followed by goat anti-mouse secondary antibody conjugated with Alexa Fluor 488 (Invitrogen, Eugene, Oreg.). Actin was stained with phalloidin conjugated with Alexa Fluor 594 (Invitrogen, Eugene, Oreg.) and nucleus was stained with 4′-6-diamidino-2-phenylindole (DAPI) (Sigma Aldrich, St. Louis, Mo.). Cells were then imaged on a Nikon TE 2000 epifluorescence microscope using GFP, Texas Red and DAPI filters. All images were collected using the NIS-Elements program (Nikon).
The live/dead viability/cytotoxicity kit for mammalian cells (Invitrogen, Eugene, Oreg.) was used for quantifying adherent cell viability on each substrate. Cells were incubated at 30-45 minutes with calcein AM (2 μM for fibroblast and 4 μM for endothelial cells) and ethidium homodimer-1 (EthD-1) (4 μM for all types of the cells). Next, epifluorescence images of six to ten random fields were collected on a Nikon TE 2000 inverted microscope using a 10× lens for NIH 3T3 and HUVEC. The average number of cells adherent on each substrate, the number of adherent live cells (stained green with calcein AM) and adherent dead cells (stained red with EthD-1) were quantified from these images using the NIS-Elements program (Nikon). Three independent experiments of cell viability were performed and the data were pooled. The average area of cell spreading was determined from three independent experiments with statistical comparison using the Student's T-test.
Time lapse imaging. Cells were pre-cultured on the patterned nanorods for 24 hours as mentioned above. Before taking a movie, non-adherent cells were removed with two gentle washes with PBS and new media was added to the dish. Phase contrast imaging was performed for 6 hours on the Nikon TE 2000 microscope with humidified incubator (In Vivo Scientific, St. Louis, Mo.). Images were collected every 5 minutes using a 10× objective.
Many biomedical implants are made of temperature-sensitive materials such as plastic. Hence, it is necessary to grow nanorods with techniques that do not require high temperature. Densely packed ZnO nanorods were fabricated with a low-temperature (95° C.) hydrothermal, solution-based growth method (Kang et al., 2007). We next deposited nano-thin films of SiO2 with controlled thickness, 50 Å, using PECVD at 50° C. according to our previously published methods (Chu et al., 2008). Transmission electron microscopy (TEM) images of the resulting nanorods with 50 Å thickness of SiO2 nano-films deposited are shown in
Cell adhesion and spreading occurs by the ligation of trans-membrane integrins to ligands (such as fibronectin) immobilized on the surface. This is followed by clustering of the integrins at the nanoscale, and subsequent formation of multi-protein, micron-scale assemblies called focal adhesions (Bershadsky et al., 2006). Focal adhesions allow force transfer from the contractile acto-myosin cytoskeleton inside the cell to the outside surface, and this allows cells to adhere to and spread on the surface. If focal adhesions are not allowed to assemble in cells that depend on anchorage for survival, this leads to weak attachment to the surface, lack of cell spreading and subsequent apoptosis (Chen et al., 1997; Re et al., 1994). Therefore, the assembly of focal adhesions was next studied using immunofluorescence microscopy.
Human umbilical vein endothelial cells (HUVECs) and NIH 3T3 fibroblasts were cultured on SiO2 nanorods which were pre-incubated with fibronectin overnight. Cells were fixed with paraformaldehyde and stained for vinculin, actin stress fibers and the nucleus. Both HUVECs and NIH 3T3 fibroblasts assembled vinculin-labeled focal adhesions on glass (
Recent work by Spatz and co-workers showed that focal adhesion assembly requires the spacing between ligated integrins to be less than 70 nm (Arnold et al., 2004; Girard et al., 2007). A spacing of more than 73 nm between ligated integrins limits attachment, spreading, and actin stress fiber formation in fibroblasts. As the diameter of the SiO2 nanorods is approximately 40˜50 nm, local integrin clustering may occur but to a very limited extent given the vertical nature and small length (500 nm) of the nanorods. Due to the spacing of 80˜100 nm, integrin clustering may not occur over multiple nanorods, preventing the assembly of contiguous focal adhesions on the micron length scale (
Other possible explanations for the reason that cells cannot spread on nanorods is the anti-wetting nature of nanostructured surfaces (Sun et al., 2005). However, cells do not spread like passive droplets, but through actin polymerization which is determined by intracellular processes (Dickinson et al., 2004) as long as initial adhesion is possible (Bershadsky et al., 2006). In addition, Kim et al. (Kim et al., 2007a) have observed that cells are easily able to engulf SiO2 nanowires with similar diameter as that studied here. This indicates that local cell-membrane interactions with nanorods are not impeded by alterations in protein adsorption.
To further investigate the question of de-wetting, we spatially patterned nanorods using a low-temperature, and patterned growth method (Kang et al., 2007). This method results in patterned nanorods that are not present inside circles, and are present outside in dense monolayers (
The number of cells adherent on SiO2 coated nanorods was significantly reduced (a reduction of 98% in fibroblasts, 82% in HUVECs) compared to cells on glass (
It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. In addition, any elements or limitations of any invention or embodiment thereof disclosed herein can be combined with any and/or all other elements or limitations (individually or in any combination) or any other invention or embodiment thereof disclosed herein, and all such combinations are contemplated with the scope of the invention without limitation thereto.
The differences of cell spreading area on ZnO flat substrate versus ZnO nanorods were statistically significant. (n=10, for NIH 3T3 and BCE, p<0.005 and for HUVEC p<0.0005).
The present application is a divisional of U.S. application Ser. No. 12/936,491, filed Dec. 13, 2010, which is the National Stage of International Application Number PCT/US2009/002686, filed Apr. 30, 2009, which claims the benefit of U.S. Provisional Application Ser. No. 61/049,262, filed Apr. 30, 2008, each of which is hereby incorporated by reference herein in its entirety, including any figures, tables, nucleic acid sequences, amino acid sequences, and drawings.
This invention was made with government support under grant number N000140710982 awarded by the Office of Naval Research and under grant number DAAD19-01-1-0603 awarded by the Army Research Office. The government has certain rights in the invention.
Number | Date | Country | |
---|---|---|---|
61049262 | Apr 2008 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12936491 | Dec 2010 | US |
Child | 14591729 | US |